Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Co., Inc. (NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines for approval at its ...

Merck & Co., Inc. operates as a healthcare company ... vIt has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates, which include patritumab ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

The results suggest that AZ and Daiichi Sankyo could be in line for ... NSCLC in combination with Keytruda in a trial sponsored by Merck. AZ licensed rights to DS-1062 in July 2020 for $1 billion ...

A new study led by researchers at Moffitt Cancer Center shows that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously believed. The study, published in ...

SNY and RHHBY announce fourth-quarter earnings. NVO's novel obesity medicine, amycretin, shows superior weight loss in study.